Conditions: Breast Cancer
Keywords: Advanced Estrogen Receptor Positive Breast Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 155
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether exemestane plus dasatinib will be well-tolerated and will increase progression-free survival (PFS) in the treatment of advanced estrogen-receptor positive (ER+) breast cancer after disease progression (PD) on a non-steroidal aromatase inhibitor (NSAI).

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Exemestane + Dasatinib intervention 2: Exemestane + Placebo
Intervention descriptions: intervention 1: Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity intervention 2: Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity

Protocol document: